In Type 2 Diabetes, Adding Once-Weekly Exenatide Doesn ' t Improve CV Outcomes (FREE)
By Amy Orciari Herman
Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS
Adding the injectable type 2 diabetes drug exenatide (Byetta) to usual care does not improve cardiovascular outcomes, according to an …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news
More News: Byetta | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Primary Care